Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab +/- Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer
NCT03087071Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2017
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab, trametinib in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2017; status: active, not recruiting.
02
Drugs
panitumumabtrametinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03087071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087071.